Literature DB >> 33883497

Fibrous Dysplasia Mimicking Skeletal Metastasis on 68Ga-FAPI PET Imaging.

Yangmeihui Song1, Chunxia Qin, Fang Liu, Xiaoli Lan.   

Abstract

ABSTRACT: 68Ga-labeled fibroblast activation protein inhibitor (68Ga-FAPI) PET imaging has been introduced for detecting many primary and metastatic tumors. However, false-positive uptakes have been reported in some benign lesions. Here, we presented a 68Ga-FAPI-avid lesion in the left temporal bone in a 41-year-old man with a history of signet ring cell gastric adenocarcinoma. The osseous lesion was finally distinguished as fibrous dysplasia according to the clinical and imaging findings. This case suggests that 68Ga-FAPI may have false-positive uptakes in bone benign lesions, which should be paid attention to in the diagnosis of bone lesions in patients with malignant tumors.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 33883497     DOI: 10.1097/RLU.0000000000003671

Source DB:  PubMed          Journal:  Clin Nucl Med        ISSN: 0363-9762            Impact factor:   7.794


  3 in total

Review 1.  Clinical summary of fibroblast activation protein inhibitor-based radiopharmaceuticals: cancer and beyond.

Authors:  Mengting Li; Muhsin H Younis; Yongxue Zhang; Weibo Cai; Xiaoli Lan
Journal:  Eur J Nucl Med Mol Imaging       Date:  2022-01-31       Impact factor: 10.057

2.  Could Fibroblast Activation Protein (FAP)-Specific Radioligands Be Considered as Pan-Tumor Agents?

Authors:  Hessamoddin Roustaei; Zahra Kiamanesh; Emran Askari; Ramin Sadeghi; Kamran Aryana; Giorgio Treglia
Journal:  Contrast Media Mol Imaging       Date:  2022-02-22       Impact factor: 3.161

3.  Emerging Role of FAPI PET Imaging for the Assessment of Benign Bone and Joint Diseases.

Authors:  Francesco Dondi; Domenico Albano; Giorgio Treglia; Francesco Bertagna
Journal:  J Clin Med       Date:  2022-08-03       Impact factor: 4.964

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.